{"preliminary_commentary":{"by_channel":{"x_thread":44,"youtube":33,"podcast":27,"bluesky_thread":3,"x_video":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03539536\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"LUMINOSITY","nct_id":"NCT03539536","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=luminosity-nct03539536. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Telisotuzumab vedotin administered via intravenous (IV) infusion every 14 days.","label":"Telisotuzumab vedotin","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-08","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":270,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Telisotuzumab vedotin","otherNames":["ABBV-399"],"type":"DRUG"}],"last_update":"2025-11-05","lead_sponsor":"AbbVie","official_title":"Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR) (Stage 1 and Stage 2)","timeFrame":"Up to approximately 3 years"},{"measure":"Number of Participants with Adverse Events (Alternate dose cohort)","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Cicin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. JTO Clin Res Rep. 2026 Mar 16;7(7):100988. doi: 10.1016/j.jtocrr.2026.100988. eCollection 2026 Jul.","pmid":"42368479","type":"DERIVED"},{"citation":"Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6.","pmid":"38843488","type":"DERIVED"}],"start_date":{"date":"2018-10-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03539536"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/luminosity-nct03539536"}